Acorda Therapeutics (ACOR) Tops Q2 EPS by 27c
Get Alerts ACOR Hot Sheet
Price: $13.50 +8.87%
Revenue Growth %: +63.1%
Financial Fact:
Operating income (loss): -5.47M
Today's EPS Names:
DSGN, ATRA, CRVS, More
Revenue Growth %: +63.1%
Financial Fact:
Operating income (loss): -5.47M
Today's EPS Names:
DSGN, ATRA, CRVS, More
Join SI Premium – FREE
Acorda Therapeutics (NASDAQ: ACOR) reported Q2 EPS of $0.42, $0.27 better than the analyst estimate of $0.15. Revenue for the quarter came in at $97.13 million versus the consensus estimate of $91.4 million.
For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FreightCar America (RAIL) Misses Q4 EPS by 6c, provides guidance
- Peraso Inc. (PRSO) Misses Q4 EPS by 844c
- DLocal Limited (DLO) Misses Q4 EPS by 5c, offers outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!